https://scholars.lib.ntu.edu.tw/handle/123456789/583129
Title: | Differences in drug resistance profiles of Mycobacterium tuberculosis isolates causing pulmonary and extrapulmonary tuberculosis in a medical centre in Taiwan, 2000-2010 | Authors: | Lai C.-C. Liu W.-L. Tan C.-K. Huang Y.-C. KUEI-PIN CHUNG MENG-RUI LEE PO-REN HSUEH |
Issue Date: | 2011 | Journal Volume: | 38 | Journal Issue: | 2 | Start page/Pages: | 125-129 | Source: | International Journal of Antimicrobial Agents | Abstract: | Few studies have investigated the drug resistance profiles of Mycobacterium tuberculosis (MTB) isolates recovered from different sites of infection. A total of 4521 non-duplicate MTB isolates, including 3723 (82.3%) from respiratory specimens and 798 (17.7%) from non-respiratory sources, were recovered from patients treated at a medical centre in Taiwan from 2000 to 2010. Trend analysis showed a significant decrease (P < 0.05) in the rates of resistance to isoniazid, rifampicin and ethambutol, a decrease in resistance to any one of four agents, namely isoniazid, rifampicin, ethambutol or streptomycin, and a decrease in resistance to both isoniazid and rifampicin (multidrug resistance) amongst pulmonary MTB isolates. A similar decrease in resistance to isoniazid and ethambutol was noted amongst non-pulmonary isolates. Rates of drug resistance were significantly higher amongst MTB isolates recovered from respiratory specimens than amongst those from non-respiratory specimens to 0.2 μg/mL isoniazid (15.3% vs. 9.4%; P < 0.0001), 1 μg/mL rifampicin (5.5% vs. 3.3%; P = 0.0108), 5 μg/mL ethambutol (7.3% vs. 3.8%; P = 0.0004), and both isoniazid and rifampicin (4.8% vs. 2.5%; P = 0.0051). Resistance rates amongst isolates causing tuberculous lymphadenitis were significantly lower than amongst those causing genitourinary tuberculosis (TB) to isoniazid (3.5% vs. 19.4%, P = 0.0012) and to isoniazid, rifampicin, ethambutol or streptomycin (9.6% vs. 22.6%, P = 0.0003). In conclusion, the rates of resistance to first-line anti-TB agents and to multiple agents differed amongst MTB isolates obtained from different infectious sources. Continuous monitoring of resistance of MTB isolates from various sites is necessary in order to establish an effective TB surveillance programme. ? 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-79959694800&doi=10.1016%2fj.ijantimicag.2011.03.016&partnerID=40&md5=a6bdb7a154a5c6ad3f1a618b2df3c180 https://scholars.lib.ntu.edu.tw/handle/123456789/583129 |
ISSN: | 0924-8579 | DOI: | 10.1016/j.ijantimicag.2011.03.016 | SDG/Keyword: | aminosalicylic acid; ethambutol; ethionamide; isoniazid; ofloxacin; rifabutin; rifampicin; streptomycin; antibiotic resistance; antibiotic sensitivity; article; ascites fluid; bacterium isolate; biliary tract biopsy; blood culture; cerebrospinal fluid; controlled study; disease surveillance; extrapulmonary tuberculosis; gastrointestinal biopsy; health care facility; human; liver biopsy; lung biopsy; lung tuberculosis; multidrug resistance; Mycobacterium tuberculosis; nonhuman; pericardial effusion; pleura effusion; priority journal; sputum smear; Taiwan; tissue culture; tracheobronchial toilet; tuberculous lymphadenitis; urogenital tuberculosis; Academic Medical Centers; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Taiwan; Tuberculosis [SDGs]SDG3 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.